Stem Cell Stocks Rise, Led By Athersys Inc. (ATHX, NBS, STEM)

Health and Healthcare

Published: December 21, 2009 2:33 pm

Last Updated: March 10, 2020 6:18 pm

Stem cell stocks (tracked in Tickerspy’s Stem Cell Stock’s Index (*RXSTM) are up over 7% today, led by Athersys Inc (NASDAQ: ATHX). Athersys Inc. rose as high as 395% this morning following news that the company has entered into a deal with Pfizer (NYSE: PFE) to develop Athersys’s MultiStem, an experimental treatment for inflammatory bowel disease. Athersys recieved an intial payment of $6 million in addition to funding for research. Should the program be successful Athersys will recieved as much as $105 million as well as royalties from sales of the drug should it come to mark.

Other stem cell stocks received a big boost from the news. Neostem Inc. (AMEX: NBS), which operates a operates a center for the collection and storage of stem cell, rose as high as 7.6%. StemCells Inc. (NASDAQ: STEM), which attempts to treat organ disorders with stem cells, climbed as high as 7.2%

Garrett W. McIntyre

The Average American Is Losing Momentum On Their Savings Every Day (Sponsor)

If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4%¹ today. Checking accounts are even worse.

But there is good news. To win qualified customers, some accounts are paying more than 7x the national average. That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn a $200 bonus and up to 7X the national average with qualifying deposits. Terms apply. Member, FDIC.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

¹https://www.fdic.gov/national-rates-and-rate-caps